Griffin P Rodgers

Education

Rodgers attended Brown University for his undergraduate, graduate, and medical degrees, and holds an MBA from Johns Hopkins University. He is a hematologist who has been board-certified in internal medicine, emergency medicine, and hematology.

NIH career

Rodgers first joined the NIH in 1984. He became the Chief of the Molecular and Clinical Hematology Branch in 1998 and the NIDDK Deputy Director in 2001. In 2006 he assumed the directorship on an acting basis and this position was made permanent in 2007 by the NIH's director at the time, Elias Zerhouni.

Research

Rodgers is a physician-scientist who studies diseases of bone marrow and is best known for his work on the molecular genetics of hemoglobinopathies and on developing a treatment for sickle cell anemia. He was a major contributor to the development of hydroxyurea therapy, which was approved by the FDA in 1998.

A 2009 study, published under the mentorship of Griffin P. Rodgers, has discovered that in human erythrocytes (peripheral blood CD34+ cells), the stem cell factor (SCF) induces γ-globin gene expression by regulating downstream transcription factor COUP-TFII, which can be a crucial molecular mechanism that has the potential for the development of effective pharmacologic strategies for treatment of patients with sickle cell disease or other β-hemoglobinopathies. However, a 2015 study by a group from University of Michigan (Ann Arbor), was unable to replicate, and hence contradicted the above 2009 study. The 2015 study concludes that "we were unable to provide evidence for COUP-TFII expression under any in vivo or in vitro culture condition from human or mouse adult erythroid cells, confirming previous microarray, as well as RNA-seq studies."

Awards and memberships

Rodgers was awarded a prestigious Mastership from the American College of Physicians in 2005.